Trailing Twelve Months Revenue Growth: Cellectar Corp (CLRB)

Public company logo of cellectar.com (CLRB)

Amidst fierce competition for radiopharmaceutical patents, the rolling annual revenue growth rate helps assess business dynamics. The current value of this metric is 0.00. Cellectar Biosciences (CLRB) maintains a competitive edge through its unique PDC platform for targeted drug delivery, which reduces toxicity. The company is currently scaling its drug portfolio and finalizing tests for its lead candidate prior to market launch.

Cellectar Biosciences (CLRB): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/17/2026

Cellectar Biosciences - analytical breakdowns and key metrics (CLRB)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:Cellectar
Brand item of Cellectar Corp

Developing radiopharmaceuticals for oncology requires an assessment of incoming cash flow stability. The calculation algorithm aggregates revenue over twelve months, excluding one-time accounting adjustments to identify the net trend. This metric measures real revenue dynamics, neutralizing distortions caused by the low-base effect. The diversification of the Cellectar Biosciences (CLRB) clinical pipeline makes this indicator a key marker of commercial viability. By analyzing this TTM year-over-year sales growth rate chart, an investor determines the structural resilience of the business.

Who Cellectar Biosciences competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) BLRX|Sales Growth YoY (TTM) Can-Fite (CANF)|Sales Growth YoY (Last Twelve Months) Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Trailing Twelve Months Sales Growth|SLXN: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)